| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $86K | — | +65.4% |
| R&D Expense | $967K | +14.7% | -29.8% |
| SG&A Expense | $1.5M | -19.8% | -30.2% |
| Interest Expense | $436K | +4.1% | +296.4% |
| Net Income | -$2.9M | +8.1% | +75.3% |
| EPS (Basic) | -$0.06 | +14.3% | +76.0% |
| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.2M | -28.8% | +1511.1% |
| Accounts Receivable | $300K | -66.7% | — |
| Inventory | $85K | -1.2% | +9.0% |
| Current Assets | $6.0M | -31.8% | +503.5% |
| Total Assets | $11.3M | -15.0% | +141.3% |
| Current Liabilities | $3.5M | -9.1% |
| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.4M | — | — |
| Investing Cash Flow | -$1.2M | — | — |
| Financing Cash Flow | $738K | — | — |
| -56.1% |
| Long-term Debt | $3.0M | -3.9% | -10.1% |
| Total Liabilities | $18.6M | -0.8% | +61.0% |
| Stockholders' Equity | -$7.3M | -33.9% | -6.4% |